The National Psoriasis Foundation (NPF) is developing an agenda for patient-centered research to help patients and their caregivers make more informed health care decisions by engaging psoriasis patients in prioritizing comparative effectiveness research (CER) topics. The NPF has created a novel patient-centered research platform known as Citizen Pscientist (CP), allowing patients with psoriasis and psoriatic arthritis to register and contribute their health data. The CP Governance Council administered an online 23-question CER survey to the CP community and held a structured meeting on December 3, 2016, with patients and researchers to review CER survey results and discuss patient-centered research priorities. Of the 2,945 patients surveyed, 792 patients responded. Three CER topics were deemed to be of high priority for the research agenda: 1) Treat-to-target therapy for psoriasis, 2) Psoriatic arthritis screening questionnaires for early detection and treatment of psoriatic arthritis, and 3) Comparative effectiveness of home-based phototherapy for psoriasis.
AbuabaraK.WanJ.TroxelA.B.Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis.J Am Acad Dermatol.2013 Feb; 68(2): 262–269.
2.
Callis DuffinK.YeungH.TakeshitaJ.Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice.Br J Dermatol.2014 Mar; 170(3): 672–680.
3.
Chiesa FuxenchZ.C.Callis DuffinK.SiegelM.Van VoorheesA.S.GelfandJ.M.. Validity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA) for objectively evaluating disease severity in patients with plaque psoriasis.J Am Acad Dermatol.2015 Nov; 73(5): 868–870.
4.
ChungJ.Callis DuffinK.TakeshitaJ.Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis.J Am Acad Dermatol.2014 Oct; 71(4): 623–632.
5.
GelfandJ.M.WanJ.Callis DuffinK.Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.Arch Dermatol.2012 Apr; 148(4): 487–494.
6.
TakeshitaJ.Callis DuffinK.ShinD.B.Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting.J Am Acad Dermatol.2014 Oct; 71(4): 633–641.
7.
TakeshitaJ.WangS.ShinD.B.Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.J Am Acad Dermatol.2014 Dec; 71(6): 1167–1175.
8.
WanJ.AbuabaraK.TroxelA.B.Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients.J Am Acad Dermatol.2012 Mar; 66(3): 376–386.
9.
WanJ.AbuabaraK.TroxelA.B.Dermatologist preferences for treatments to compare in future randomized controlled comparative effectiveness trials for moderate to severe psoriasis.Arch Dermatol.2012 Apr; 148(4): 539–541.
10.
YeungH.WanJ.Van VoorheesA.S.Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.J Am Acad Dermatol.2013 Jan; 68(1): 64–72.
11.
KvienT.K.MikkelsenK.NordvagB.Y.. Results from controlled clinical trials: how relevant for clinical practice?J Rheumatol.2003 Jun; 30(6): 1135–1137.
12.
BombardierC.MaetzelA.. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?Ann Rheum Dis.1999 Nov; 58 Suppl 1: I82–85.
13.
AtarD.BirkelandK.I.UhligT.. ‘Treat to target’: moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis.Ann Rheum Dis.2010 Apr; 69(4): 629–630.
14.
SmolenJ.S.AletahaD.BijlsmaJ.W.Treating rheumatoid arthritis to target: recommendations of an international task force.Ann Rheum Dis.2010 Apr; 69(4): 631–637.
15.
GersteinH.C.MillerM.E.ByingtonR.P.Effects of intensive glucose lowering in type 2 diabetes.N Eng J Med.2008 Jun; 358(24): 2545–2559.
16.
SmithS.C.Jr.GrundyS.M.. 2013ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol.J Amer Coll Cardiol. 2014 Aug;64(6): 601–612.
17.
CoatesL.C.CookR.LeeK.A.ChandranV.GladmanD.D.. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort.Arthritis Care Res (Hoboken).2010 Jul; 62(7): 970–976.
18.
CoatesL.C.FransenJ.HelliwellP.S.. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment.Ann Rheum Dis.2010 Jan; 69(1): 48–53.
19.
CoatesL.C.HelliwellP.S.. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data.Arthritis Care Res (Hoboken).2010 Jul; 62(7): 965–969.
20.
CoatesL.C.MoverleyA.R.McParlandL.Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.Lancet.2015 Dec; 386(10012): 2489–2498.
21.
KavanaughA.van der HeijdeD.BeutlerA.Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study.Arthritis Care Res (Hoboken).2016 Feb; 68(2): 267–274.
22.
ArmstrongA.W.SiegelM.P.BagelJ.From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis.J Am Acad Dermatol.2017 Feb; 76(2): 290–298.
23.
HaroonM.GallagherP.FitzGeraldO.. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis.Ann Rheum Dis.2015 Jun; 74(6): 1045–1050.
24.
HarleP.LetschertK.WittigB.MrowietzU.. Sensitivity of the GEPARD Patient Questionnaire to Identify Psoriatic Arthritis in Patients with Psoriasis in Daily Practice: The GEPARD-Life Study.Dermatology.2016; 232(5): 597–605.
25.
MishraS.KancharlaH.DograS.SharmaA.. Comparison of the Four Validated Psoriatic Arthritis Screening Tools in Diagnosing Psoriatic Arthritis in Patients with Psoriasis [COMPAQ Study].Br J Dermatol.2016 Aug; 176(3): 765–770.
26.
LarkoO.SwanbeckG.. Home solarium treatment of psoriasis.Br J Dermatol.1979 Jul; 101(1): 13–16.
27.
RajparaA.N.O'NeillJ.L.NolanB.V.YentzerB.A.FeldmanS.R.. Review of home phototherapy.Dermatol Online J.2010 Dec; 16(12): 2.
28.
TakeshitaJ.ArmstrongA.DuffinK.C.RobertsonA.D.AttorR.GelfandJ.M.. Patient Reported Priorities for Comparative Effectiveness Research in Psoriasis. Paper presented at: 4th Congress of the Psoriasis International Network; July 4–6, 2013; Paris, France.
29.
CameronH.YuleS.MoseleyH.DaweR.S.FergusonJ.. Taking treatment to the patient: development of a home TL-01 ultraviolet B phototherapy service.Br J Dermatol.2002 Nov; 147(5): 957–965.
30.
HaykalK.A.DesGroseilliersJ.P.. Are narrow-band ultraviolet B home units a viable option for continuous or maintenance therapy of photoresponsive diseases?J Cutan Med Surg.2006 Sep-Oct; 10(5): 234–240.
31.
KoekM.B.BuskensE.van WeeldenH.SteegmansP.H.Bruijnzeel-KoomenC.A.SigurdssonV.. Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study).BMJ.2009 May; 338: b1542.
32.
VelezN.F.Wei-PassaneseE.X.HusniM.E.ModyE.A.QureshiA.A.. Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic.Arch Dermatol Res.2012 Jan; 304(1): 7–13.
33.
ArmstrongA.W.. Improving Specialty-Care Delivery in Chronic Skin Diseases.University of Southern Califronia, Los Angeles, California: Patient-Centered Outcomes Research Institute; 2014.
